NCT05586074View on ClinicalTrials.gov

HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

PHASE3RecruitingINTERVENTIONAL
Enrollment

324

Participants

Timeline

Start Date

March 3, 2023

Primary Completion Date

March 10, 2026

Study Completion Date

June 14, 2027

Conditions
Leukemia, Acute Myeloid (AML)
Interventions
DRUG

Clifutinib

tablet, oral

DRUG

LoDAC

subcutaneous (SC) or intravenous (IV) injection

DRUG

Azacitidine

SC or IV

DRUG

Decitabine

IV

DRUG

Ara-C±IDA

SC and IV

DRUG

FLAG-IDA

SC and IV

Trial Locations (1)

Unknown

RECRUITING

the First Affiliated Hospital,College of Medicine,Zhejiang University, Hanzhou

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY